References
1. Giulino-Roth L, Keller FG, Hodgson DC, Kelly KM. Current approaches
in the management of low risk Hodgkin lymphoma in children and
adolescents. Br J Haematol. 2015;169:647–60.
2. Kelly KM. Management of children with high-risk Hodgkin lymphoma. Br
J Haematol. 2012;157:3–13.
3. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F,
et al. Long-term results of combined chemotherapy-radiotherapy approach
in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP
plus radiotherapy. J Clin Oncol. 1987;5:27–37.
4. Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A,
et al. Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD
Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed
Advanced-Stage Hodgkin’s Lymphoma: A Study From the Intergruppo Italiano
Linfomi. J Clin Oncol. 2011;29:4227–33.
5. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al.
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma
in Adults. J Clin Oncol. 2004;22:1864–71.
6. Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, et al.
Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of
semen quality before and after different chemotherapy regimens. Hum
Reprod. 2016;31:263–72.
7. Straus DJ. Long-term survivorship at a price: late-term,
therapy-associated toxicities in the adult Hodgkin lymphoma patient.
Ther Adv Hematol. 2011;2:111–9.
8. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter
JN, et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage
Hodgkin’s Lymphoma. N Engl J Med. 2012;366:399–408.
9. Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ,
et al. Dose-Intensive Response-Based Chemotherapy and Radiation Therapy
for Children and Adolescents With Newly Diagnosed Intermediate-Risk
Hodgkin Lymphoma: A Report From the Children’s Oncology Group Study
AHOD0031. J Clin Oncol. 2014;32:3651–8.
10. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE,
Sposto R, et al. A risk-adapted, response-based approach using ABVE-PC
for children and adolescents with intermediate- and high-risk Hodgkin
lymphoma: the results of P9425. Blood. 2009;114:2051–9.
11. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, et
al. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma
(HL) Treated on US Cooperative Group Protocols: An Adult Intergroup
(E2496) and Children’s Oncology Group (COG AHOD0031) Comparative
Analysis. Blood. 2015;126:2636–2636.
12. Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden SL, et al.
Subsequent malignant neoplasms among children with Hodgkin lymphoma: a
report from the Children’s Oncology Group. Blood. 2021;137:1449–56.
13. Stieglitz E, Dinh T, Phelps AS, Pampaloni MH, Olshen AB, Robbins E.
ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult
Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis
of 28 Consecutive Patients. J Pediatr Hematol Oncol. 2018;40:290–4.
14. Ingley KM, Nadel HR, Potts JE, Wilson DC, Eftekhari A, Deyell RJ.
The Utility of PET/CT in Guiding Radiotherapy Reduction for Children
With Hodgkin Lymphoma Treated With ABVD. J Pediatr Hematol Oncol.
2020;42:e87–93.
15. Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma:
maximizing efficacy and minimizing toxicity. Semin Radiat Oncol.
2007;17:230–42.
16. Frick MA, Vachani CC, Hampshire MK, Bach C, Arnold-Korzeniowski K,
Metz JM, et al. Patient-Reported Survivorship Care Practices and Late
Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma. JCO Clin
Cancer Inform. 2018;2:1–10.
17. Chow LML, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, et
al. Survival and Late Effects in Children With Hodgkin’s Lymphoma
Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation. J Clin
Oncol. 2006;24:5735–41.
18. Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, et al.
Survival by Race and Ethnicity in Pediatric and Adolescent Patients With
Hodgkin Lymphoma: A Children’s Oncology Group Study. J Clin Oncol Off J
Am Soc Clin Oncol. 2019;37:3009–17.
19. Kahn JM, Keegan THM, Tao L, Abrahão R, Bleyer A, Viny AD. Racial
disparities in the survival of American children, adolescents, and young
adults with acute lymphoblastic leukemia, acute myelogenous leukemia,
and Hodgkin lymphoma. Cancer. 2016;122:2723–30.
20. Grubb WR, Neboori HJ, Diaz AD, Li H, Kwon D, Panoff J. Racial and
Ethnic Disparities in the Pediatric Hodgkin Lymphoma Population. Pediatr
Blood Cancer. 2016;63:428–35.
Figure Legends
Figure 1 – Event-free survival and overall survival. A:
Event-free survival as defined by time to first relapse or last-known
follow-up if still in first remission. B: Overall survival, as defined
by time to death or to last-known follow-up if still alive. ABVD:
Adriamycin, Bleomycin, Vinblastine, Dacarbazine. ABVE-PC: Adriamycin,
Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide
ImageEFSOS